EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Promising anticancer activity of cromolyn in colon cancer: in vitro and in vivo analysis

Amin Aliabadi, Mohammad Reza Haghshenas, Razie Kiani, Mohammad Reza Panjehshahin, Nasrollah Erfani

Journal of Cancer Research and Clinical Oncology · 2024

DOI: 10.1007/s00432-024-05741-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cancer Research and Clinical Oncology, 2024. Verfasst von Amin Aliabadi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. Hauptthemen laut MEDLINE: Colonic Neoplasms, Apoptosis, Cell Proliferation, Cromolyn Sodium. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shiraz University of Medical Sciences, Shiraz, Iran, Shiraz Institute for Cancer Research, Shiraz, Iran.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Colon cancer is a prevalent cancer globally, representing approximately 10% of all cancer cases and accounting for 10% of all cancer-related deaths. Therefore, finding new therapeutic methods with high efficiency will be very valuable. Cromolyn ( C ), a common anti-allergic and mast cell membrane stabilizing drug, has recently shown valuable anti-cancer effects in several studies. This study was designed to investigate the anti-cancer activity of cromolyn on colon cancer in vitro and in vivo and to determine values such as selectivity index and survival effect.

Methods

HT-29 (colon cancer) and MCF-10 (normal epithelial) cell lines were treated with C and Doxorubicin (DOX; Positive control). IC50 values and the effects of C and DOX on apoptosis were explored using methyl thiazole diphenyl-tetrazolium bromide (MTT) assay and Annexin V/PI Apoptosis Assay Kit. To investigate in an animal study, colon cancer was subcutaneously induced by CT26 cells (mouse colon cancer) in bulb/c mice. Mice were treated with 0.05 LD50 intraperitoneal every other day for 35 days. After the death of mice, tumor volume, tumor weight, and survival rate were evaluated.

Results

C selectively and significantly suppressed the proliferation of cancer cells in a dose-dependent manner. The IC50 values for the MCF-10 and HT29 cell lines were 7.33 ± 0.78 μM and 2.33 ± 0.6 μM, respectively. Notably, the selective index (SI) highlighted that C displayed greater selectivity in inhibiting cancer cell growth compared to DOX, with SI values of 3.15 and 2.60, respectively. C exhibited higher effectiveness and selectivity in inducing apoptosis in cancer cells compared to DOX, with a significant p-value (61% vs. 52%, P-value ≤ 0.0001). Also, in mice bearing colon cancer, C reduced the tumor volume (6317 ± 1685mm 3 ) and tumor weight (9.8 ± 1.6 g) compared to the negative control group (weight 12.45 ± 0.9 g; volume 7346 ± 1077) but these values were not statistically significant (P ≤ 0.05).

Conclusion

Our study showed that cromolyn is a selective and strong drug in inhibiting the proliferation of colon cancer cells. Based on our results, the efficacy of C in vitro analysis (MTT assays and apoptosis), as well as animal studies is competitive with the FDA-approved drug doxorubicin. C is very promising as a low-complication and good-efficacy drug for cancer drug repositioning. This requires clinical research study designs to comprehensively evaluate its anti-cancer effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colonic NeoplasmsApoptosisCell ProliferationCromolyn SodiumAnimalsHumansMiceDoxorubicinMice, Inbred BALB CHT29 CellsAntineoplastic AgentsXenograft Model Antitumor AssaysCell Line, Tumor

Stichwörter der Autor:innen

ApoptosisColon cancerCromolynDrug repositioning

Substanzen

Cromolyn SodiumDoxorubicinAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Pharmacology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Department of Pharmacology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. panjeshm@sums.ac.ir.
  • Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. erfanin@sums.ac.ir.
  • Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. erfanin@sums.ac.ir.

Förderung

  • Shiraz University of Medical Sciences, Shiraz, Iran
  • Shiraz Institute for Cancer Research, Shiraz, Iran

Zitieren

APA

Aliabadi, A., Haghshenas, M. R., Kiani, R., Panjehshahin, M. R., & Erfani, N. (2024). Promising anticancer activity of cromolyn in colon cancer: in vitro and in vivo analysis. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-024-05741-2

Vancouver

Aliabadi A, Haghshenas MR, Kiani R, Panjehshahin MR, Erfani N. Promising anticancer activity of cromolyn in colon cancer: in vitro and in vivo analysis. Journal of Cancer Research and Clinical Oncology. 2024. doi:10.1007/s00432-024-05741-2

BibTeX
@article{Aliabadi2024,
  author = {Aliabadi, Amin and Haghshenas, Mohammad Reza and Kiani, Razie and Panjehshahin, Mohammad Reza and Erfani, Nasrollah},
  title = {Promising anticancer activity of cromolyn in colon cancer: in vitro and in vivo analysis},
  journal = {Journal of Cancer Research and Clinical Oncology},
  year = {2024},
  doi = {10.1007/s00432-024-05741-2}
}
Kostenlos starten →